source
- Braveheart Bio raises $382.5M in IPO to fund phase 3 trial of cardiac drugBraveheart Bio, a San Francisco biotech, completed an IPO that raised $382.5 million, exceeding its original target. The company increased the share count to 21.2 million and set the price at $18…
- Medline recalls Hudson RCI neonatal heated wire breathing circuits over connector overheating riskMedline Industries announced a nationwide recall of its Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits. The recall was triggered after the company received reports of sporadic failures i…